Loading
Doctors who could turn discoveries into trials are buried in clinical work. Hospitals would guarantee them research time and recover the cost from the trials and grants they bring in.
Cancer hospitals create a protected-time scheme (for example 40% for five years) for clinician-scientists leading translational projects, funded from a revolving pool seeded by philanthropy and repaid from the indirect costs of grants and per-patient trial income those clinicians generate. Selection is by translational plan and mentorship, not by publication record. Clinician-scientists are the people who take a lab finding into a phase 1 protocol, yet their numbers are falling in most countries because clinical productivity pays and research time is the first thing cut.
Shares Translational research: crossing the valley of death, The valley of death between lab and product.
Shares Translational research: crossing the valley of death, The valley of death between lab and product.
Shares Translational research: crossing the valley of death, The valley of death between lab and product.
Shares Translational research: crossing the valley of death, The valley of death between lab and product.
Shares Translational research: crossing the valley of death, The valley of death between lab and product.
Shares Translational research: crossing the valley of death, The valley of death between lab and product.
Shares Translational research: crossing the valley of death, The valley of death between lab and product.
Shares Translational research: crossing the valley of death, The valley of death between lab and product.